Gyrodyne (GYRO)
Market Price (3/30/2026): $8.06 | Market Cap: $1.2 MilSector: Real Estate | Industry: Real Estate Services
Gyrodyne (GYRO)
Market Price (3/30/2026): $8.06Market Cap: $1.2 MilSector: Real EstateIndustry: Real Estate Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 47% | Weak multi-year price returns2Y Excs Rtn is -26%, 3Y Excs Rtn is -65% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 392% | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -1.8% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44% | ||
| Key risksGYRO key risks include [1] a multi-year lack of revenue growth and stagnant earnings, Show more. |
| Low stock price volatilityVol 12M is 47% |
| Weak multi-year price returns2Y Excs Rtn is -26%, 3Y Excs Rtn is -65% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 392% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -1.8% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44% |
| Key risksGYRO key risks include [1] a multi-year lack of revenue growth and stagnant earnings, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Extended Liquidation Timeline and Reduced Net Asset Value (NAV).
Gyrodyne operates on a liquidation basis, aiming to sell its real estate assets and distribute proceeds to shareholders. The estimated liquidation date was extended to December 31, 2027, with potential further extensions to August 2028 if options related to a major asset sale are exercised. This prolonged timeline increased estimated operating and liquidation costs and led to a re-measurement of assets and liabilities, resulting in a negative impact of $2.72 million as of September 30, 2025. This extension of the timeline and associated costs contributed to a decrease in the estimated Net Asset Value (NAV) per share, from approximately $14.83 in June 2025 to $14.72 by November 2025.
2. Contingencies and Delays in Major Flowerfield Asset Sale.
While Gyrodyne entered into a definitive agreement in July 2025 to sell a 49-acre parcel at its Flowerfield complex for $24.0-$28.74 million, the transaction is subject to significant contingencies and delays. The closing of this sale is dependent on obtaining subdivision and site-plan approvals within an 18-month period, with the latest estimated closing potentially extending until December 2027 or even August 2028. This protracted and conditional nature of a key asset disposition introduces substantial execution risk and uncertainty for investors, diminishing the immediate value realization anticipated from the sale.
Show more
Stock Movement Drivers
Fundamental Drivers
The -15.9% change in GYRO stock from 11/30/2025 to 3/29/2026 was primarily driven by a -15.9% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.50 | 7.99 | -15.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | 0.0% |
| Net Income Margin (%) | 0.9% | 0.9% | 0.0% |
| P/E Multiple | 26.4 | 22.2 | -15.9% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -15.9% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GYRO | -15.9% | |
| Market (SPY) | -5.3% | 25.7% |
| Sector (XLRE) | -2.9% | 22.4% |
Fundamental Drivers
The -22.1% change in GYRO stock from 8/31/2025 to 3/29/2026 was primarily driven by a -22.1% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.25 | 7.99 | -22.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | 0.0% |
| Net Income Margin (%) | 0.9% | 0.9% | 0.0% |
| P/E Multiple | 28.5 | 22.2 | -22.1% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -22.1% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GYRO | -22.1% | |
| Market (SPY) | 0.6% | 6.6% |
| Sector (XLRE) | -3.7% | 11.8% |
Fundamental Drivers
The -8.8% change in GYRO stock from 2/28/2025 to 3/29/2026 was primarily driven by a -8.8% change in the company's P/E Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.76 | 7.99 | -8.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | 0.0% |
| Net Income Margin (%) | 0.9% | 0.9% | 0.0% |
| P/E Multiple | 24.3 | 22.2 | -8.8% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -8.8% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GYRO | -8.8% | |
| Market (SPY) | 9.8% | 7.9% |
| Sector (XLRE) | -4.1% | 6.6% |
Fundamental Drivers
The -0.1% change in GYRO stock from 2/28/2023 to 3/29/2026 was primarily driven by a -0.1% change in the company's P/E Multiple.| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.00 | 7.99 | -0.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 5 | 0.0% |
| Net Income Margin (%) | 0.9% | 0.9% | 0.0% |
| P/E Multiple | 22.2 | 22.2 | -0.1% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -0.1% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GYRO | -0.1% | |
| Market (SPY) | 69.4% | 5.2% |
| Sector (XLRE) | 16.1% | 8.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GYRO Return | -29% | -30% | 23% | -10% | 2% | -11% | -50% |
| Peers Return | 18% | -11% | 25% | 22% | 31% | 4% | 117% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| GYRO Win Rate | 42% | 33% | 58% | 33% | 33% | 33% | |
| Peers Win Rate | 57% | 43% | 58% | 67% | 63% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| GYRO Max Drawdown | -35% | -30% | -4% | -23% | -17% | -11% | |
| Peers Max Drawdown | -12% | -24% | -9% | -12% | -6% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: WELL, VTR, OHI, SBRA, PLD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | GYRO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -54.4% | -25.4% |
| % Gain to Breakeven | 119.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -25.3% | -33.9% |
| % Gain to Breakeven | 33.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -25.3% | -19.8% |
| % Gain to Breakeven | 33.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -71.1% | -56.8% |
| % Gain to Breakeven | 245.7% | 131.3% |
| Time to Breakeven | 487 days | 1,480 days |
Compare to WELL, VTR, OHI, SBRA, PLD
In The Past
Gyrodyne's stock fell -54.4% during the 2022 Inflation Shock from a high on 4/9/2021. A -54.4% loss requires a 119.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Gyrodyne (GYRO)
AI Analysis | Feedback
A regional commercial landlord, similar to a smaller Boston Properties, but with a specialized focus on medical office buildings.
Imagine them as a landlord for businesses, particularly medical practices, similar to how Simon Property Group is a landlord for retail stores in shopping malls.
AI Analysis | Feedback
- Commercial Property Ownership: Acquiring and holding a portfolio of diverse commercial real estate properties.
- Commercial Property Leasing: Providing commercial spaces for rent to tenants, with a notable emphasis on medical office products.
- Commercial Property Management: Overseeing the operations, maintenance, and tenant relations for its owned commercial properties.
AI Analysis | Feedback
Gyrodyne, LLC (GYRO) sells primarily to other companies by leasing them commercial property space. Based on the company's description, its major customers fall into the following categories:
- Medical practices, clinics, hospitals, and other healthcare providers, given Gyrodyne's emphasis on medical office product.
- Various other businesses requiring commercial office space, retail space, or light industrial space, reflecting its diverse commercial property portfolio.
AI Analysis | Feedback
nullAI Analysis | Feedback
Gary Jay Fitlin Chief Executive Officer, President, Chief Financial Officer & Treasurer
Mr. Fitlin has served as the Chief Executive Officer and President of Gyrodyne, LLC since May 1, 2017. He also holds the titles of Chief Financial Officer and Treasurer, roles he assumed upon joining the company in October 2009. From August 2012 to February 2013, Mr. Fitlin served as interim President and Chief Executive Officer. Prior to his tenure at Gyrodyne, he was the Director of Accounting Implementation for Lexington Realty Trust, a publicly traded real estate investment trust, from July 2006 to March 2008, where his responsibilities included mergers and acquisitions. Before that, he held senior financial officer positions at various other publicly traded companies, overseeing areas such as mergers and acquisitions, global accounting, management reporting, tax compliance and planning, financial systems, risk management, and contract administration. Mr. Fitlin is a Certified Public Accountant and an alumnus of Arthur Andersen & Co.
Peter Pitsiokos Executive Vice President, Chief Operating Officer, Chief Compliance Officer & Corporate Secretary
Mr. Pitsiokos serves as the Executive Vice President, Chief Operating Officer, Chief Compliance Officer, and Corporate Secretary for Gyrodyne, LLC.
Dawn Ibraham Controller
Ms. Ibraham is the Controller at Gyrodyne, LLC.
AI Analysis | Feedback
The key risks to Gyrodyne, LLC (GYRO) are primarily associated with its ongoing strategy of planned dissolution and the inherent challenges in executing this process.Key Risks to Gyrodyne (GYRO)
- Planned Dissolution and Property Sale Risks: Gyrodyne is actively pursuing a planned dissolution by the end of 2026, which involves the disposition of all its real property assets. This process faces significant risks, including potential delays or denials in obtaining necessary entitlements and permits, community opposition, and ongoing legal challenges such as the Article 78 Proceeding, which could further complicate property sales. The illiquidity of real estate assets also presents a risk, as it may hinder the timely sale of properties at favorable prices, directly impacting property values and shareholder distributions.
- Market and Economic Risks: Fluctuations in real estate market values, interest rates, and broader economic conditions pose substantial risks to Gyrodyne's liquidation strategy. Elevated interest rates and inflation, for example, have already affected the company's operations, leading to delays in securing entitlements and potentially impacting occupancy rates and the ultimate proceeds from property sales.
- Operational and Financial Challenges During Liquidation: As Gyrodyne progresses towards dissolution, it anticipates ongoing operating losses due to administrative and land entitlement expenses that may exceed rental income. The company is also exposed to risks related to the loss of major tenants and its reliance on debt financing. Increased estimated liquidation and operating costs further impact overall liquidity and the final distributions to shareholders.
AI Analysis | Feedback
The long-term impact of telemedicine and the broader shift towards virtual care models on the demand for physical medical office space represents a clear emerging threat. While medical facilities remain essential for procedures, diagnostics, and in-person examinations, a sustained increase in the proportion of healthcare services delivered remotely could reduce the overall need for, or optimize the size and configuration of, traditional medical office properties, potentially affecting occupancy rates and lease values for Gyrodyne.
AI Analysis | Feedback
Gyrodyne, LLC (NASDAQ: GYRO) focuses on owning, leasing, and managing diverse commercial properties, with a significant emphasis on medical office buildings. The firm's operations are concentrated in the New York metropolitan area, specifically Long Island and Westchester County, New York.
The addressable market for Gyrodyne's main products and services can be understood within the broader U.S. commercial real estate market and, more specifically, the medical office real estate sector.
Medical Office Real Estate Market
The U.S. medical office market is valued at over $150 billion and is experiencing an annual demand growth of 3-4%. While a precise market size specifically for Long Island and Westchester County, New York, is not readily available, the Tri-State New York metro area (which includes NYC, New Jersey, Connecticut, and Long Island) shows strong demand in the medical office market. New York City is also identified as an area with elevated medical office construction projects.
Overall Commercial Real Estate Market
The broader United States commercial real estate market provides context for Gyrodyne's diversified portfolio. This market was valued at USD 742.3 billion in 2025 and is projected to reach USD 995.6 billion by 2034, with a compound annual growth rate of 3.32% from 2026-2034. Other estimates place the U.S. commercial real estate market size at USD 1.7 trillion in 2025, expected to grow to USD 2.02 trillion by 2031, at a CAGR of 2.91%. In terms of square footage, the U.S. commercial real estate market comprised approximately 5.9 million buildings totaling 97 billion square feet as of 2018.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Gyrodyne (GYRO)
Gyrodyne, LLC (NASDAQ: GYRO) is undergoing a strategic liquidation and redevelopment phase, with its future financial performance primarily driven by the realization of value from its remaining real estate assets rather than traditional recurring operational revenue growth. The company's revenue is currently negligible, stemming largely from investment income.
The primary expected drivers of future revenue growth (or asset value realization) for Gyrodyne over the next 2-3 years include:
- Sale of the Flowerfield Property Parcel: A significant driver is the agreement to sell a 49-acre parcel of its Flowerfield complex in Smithtown, New York, as part of its strategic liquidation plan. This transaction, announced in August 2025, has an estimated final purchase price ranging from $24,000,000 to $28,740,000.
- Zoning and Redevelopment of Remaining Flowerfield Property: The company's success is highly dependent on securing zoning approvals for its remaining Flowerfield property. This could lead to further sales or partnerships with developers to unlock underlying value. The anticipated timeline for completing asset sales and liquidations has been extended to December 31, 2027, influenced by regulatory processes and market conditions.
- Subdivision and Value Enhancement of Cortlandt Manor Property: Gyrodyne also owns a medical office park in Cortlandt Manor, New York, which is currently undergoing a subdivision application. The goal of this application is to enhance the property's value, contributing to overall asset realization.
- Strategic Land Entitlement Efforts: Ongoing investments in land entitlement costs are focused on enhancing the overall value of Gyrodyne's properties. These efforts are crucial for maximizing the proceeds from eventual asset dispositions.
AI Analysis | Feedback
Share Issuance
- Gyrodyne completed a rights offering on March 7, 2024, generating approximately $4.4 million in net proceeds.
- In this rights offering, all 625,000 common shares offered were purchased at $8 per share, resulting in $5 million in gross proceeds.
- The shares issued in the rights offering consisted of 353,164 shares from basic subscription privileges and 271,836 shares from over-subscription privileges.
Capital Expenditures
- In 2024, Gyrodyne incurred approximately $422,000 in land entitlement costs for its Flowerfield and Cortlandt Manor properties.
- The company anticipates an additional $1.24 million in land entitlement costs through 2026 to increase development flexibility for its properties.
- Gyrodyne incurred approximately $315,500 in land entitlement costs in 2022 and $567,000 in 2021, primarily for engineering costs, legal fees, and real estate taxes to support entitlement efforts aimed at maximizing property value for eventual sale.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Gyrodyne Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to GYRO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02272026 | KRC | Kilroy Realty | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02202026 | AAT | American Assets Trust | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -0.2% | -0.2% | -1.5% |
| 12122025 | LINE | Lineage | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 11.7% | 11.7% | -7.3% |
| 11302025 | OHI | Omega Healthcare Investors | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 6.7% | 6.7% | -6.0% |
| 10312025 | ADC | Agree Realty | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 11.8% | 11.8% | -2.8% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 63.22 |
| Mkt Cap | 25.9 |
| Rev LTM | 3,512 |
| Op Inc LTM | 550 |
| FCF LTM | 940 |
| FCF 3Y Avg | 742 |
| CFO LTM | 1,263 |
| CFO 3Y Avg | 1,057 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.7% |
| Rev Chg 3Y Avg | 11.5% |
| Rev Chg Q | 15.2% |
| QoQ Delta Rev Chg LTM | 3.7% |
| Op Mgn LTM | 24.4% |
| Op Mgn 3Y Avg | 23.8% |
| QoQ Delta Op Mgn LTM | -0.5% |
| CFO/Rev LTM | 36.6% |
| CFO/Rev 3Y Avg | 53.2% |
| FCF/Rev LTM | 35.9% |
| FCF/Rev 3Y Avg | 53.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 25.9 |
| P/S | 8.9 |
| P/EBIT | 21.7 |
| P/E | 33.7 |
| P/CFO | 19.2 |
| Total Yield | 3.7% |
| Dividend Yield | 1.1% |
| FCF Yield 3Y Avg | 5.9% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.6% |
| 3M Rtn | 2.6% |
| 6M Rtn | 11.3% |
| 12M Rtn | 21.6% |
| 3Y Rtn | 105.1% |
| 1M Excs Rtn | 1.1% |
| 3M Excs Rtn | 10.9% |
| 6M Excs Rtn | 16.4% |
| 12M Excs Rtn | 10.9% |
| 3Y Excs Rtn | 54.6% |
Price Behavior
| Market Price | $7.99 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 08/18/1995 | |
| Distance from 52W High | -25.6% | |
| 50 Days | 200 Days | |
| DMA Price | $9.30 | $8.90 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -14.1% | -10.3% |
| 3M | 1YR | |
| Volatility | 42.9% | 68.8% |
| Downside Capture | 1.27 | 0.69 |
| Upside Capture | 50.84 | 52.01 |
| Correlation (SPY) | 16.7% | 4.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.13 | 0.48 | 0.52 | 0.11 | 0.11 | 0.09 |
| Up Beta | -0.07 | 0.90 | 0.93 | 0.77 | 0.07 | 0.03 |
| Down Beta | 0.14 | 0.91 | 1.06 | 0.88 | 0.23 | 0.12 |
| Up Capture | -16% | -2% | -6% | -45% | 5% | 3% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 4 | 6 | 8 | 27 | 54 | 158 |
| Down Capture | -32% | 32% | 38% | -33% | 11% | 24% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 3 | 6 | 10 | 33 | 57 | 181 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GYRO | |
|---|---|---|---|---|
| GYRO | 24.4% | 53.5% | 1.69 | - |
| Sector ETF (XLRE) | -1.0% | 16.3% | -0.24 | 11.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 16.0% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 5.0% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 9.4% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 15.1% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | -8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GYRO | |
|---|---|---|---|---|
| GYRO | 2.3% | 54.4% | 0.32 | - |
| Sector ETF (XLRE) | 3.9% | 19.0% | 0.11 | 9.5% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 13.1% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 8.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 4.8% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 11.1% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GYRO | |
|---|---|---|---|---|
| GYRO | 0.2% | 34.8% | 0.12 | - |
| Sector ETF (XLRE) | 5.9% | 20.4% | 0.25 | 1.4% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 0.9% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 0.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 2.1% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 1.9% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2015 | 08/14/2015 | 10-Q |
| 03/31/2015 | 05/15/2015 | 10-Q |
| 12/31/2014 | 03/31/2015 | 10-K |
| 09/30/2014 | 11/05/2014 | 10-Q |
| 06/30/2014 | 08/08/2014 | 10-Q |
| 03/31/2014 | 05/12/2014 | 10-Q |
| 12/31/2013 | 03/25/2014 | 10-K |
| 09/30/2013 | 11/12/2013 | 10-Q |
| 06/30/2013 | 08/09/2013 | 10-Q |
| 03/31/2013 | 05/10/2013 | 10-Q |
| 12/31/2012 | 03/18/2013 | 10-K |
| 09/30/2012 | 11/14/2012 | 10-Q |
| 06/30/2012 | 08/13/2012 | 10-Q |
| 09/30/2011 | 11/09/2011 | 10-Q |
| 06/30/2011 | 08/12/2011 | 10-Q |
| 03/31/2011 | 05/12/2011 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.